We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
- Authors
Papadimitrakopoulou, Vasiliki A.; Frank, Steven J.; Cohen, Ezra W.; Hirsch, Fred R.; Myers, Jeffrey N.; Heymach, John V.; Lin, Heather; Tran, Hai T.; Chen, Changhu R.; Jimeno, Antonio; Nedzi, Lucien; Vasselli, Joseph R.; Lowe, Elizabeth S.; Raben, David
- Abstract
Background Vandetanib, added to cisplatin and radiation therapy (RT) overcomes chemoradiation therapy (CRT) and epidermal growth factor receptor (EGFR) inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and models. Methods Patients with previously untreated HNSCC received vandetanib daily for 14 days (starting dose 100 mg) and then vandetanib + RT (2.2 Gy/day, 5 days/week) for 6 weeks (regimen 1) or vandetanib + RT (2 Gy/day, 5 days/week) + cisplatin (30 mg/m2 weekly) for 7 weeks (regimen 2). The primary objective was the maximum tolerated dose (MTD) of vandetanib with RT +/- cisplatin. Results Of 33 treated patients, 30 completed therapy (regimen 1, n = 12; regimen 2, n = 18). MTD in regimen 2 was 100 mg (3 dose limiting toxicities [DLTs] at 200 mg), whereas regimen 1 was stopped because of poor recruitment (1 DLT at 200 mg). Most common grade ≥3 adverse events (AEs) were dysphagia (30%), stomatitis (33%), and mucosal inflammation (27%). Five patients discontinued vandetanib because of AEs. Conclusion Vandetanib with CRT was feasible. © 2015 Wiley Periodicals, Inc. Head Neck 38: 439-447, 2016
- Subjects
RADIOTHERAPY; ELECTROTHERAPEUTICS; CISPLATIN; ALKYLATING agents; SQUAMOUS cell carcinoma
- Publication
Head & Neck, 2016, Vol 38, Issue 3, p439
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.23922